ArticleThe Journal of clinical investigation2013
Cross-species malaria immunity induced by chemically attenuated parasites.
Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 84 citations in OpenAlex.
- Trial
- ATG5-regulated CCL2/MCP-1 production in myeloid cells selectively modulates anti-malarial CD4Autophagy · 2024Article
- Profiling the antibody response of humans protected by immunization with Plasmodium vivax radiation-attenuated sporozoites.Scientific reports · 2024Article
- Malaria Vaccines: Progress to Date.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Malaria vaccines: the 60-year journey of hope and final success-lessons learned and future prospects.Tropical medicine and health · 2023Review
- Live Vaccination with Blood-StageVaccines · 2022Article
- Selective Targeting of Breast Cancer by Tafuramycin A Using SMA-Nanoassemblies.Molecules (Basel, Switzerland) · 2021Article
- Whole-Killed Blood-Stage Vaccine: Is It Worthwhile to Further Develop It to Control Malaria?Frontiers in microbiology · 2021Review
- The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design.Frontiers in immunology · 2020Review
- Malaria vaccines since 2000: progress, priorities, products.NPJ vaccines · 2020Review
- A genetically hmgb2 attenuated blood stage P. berghei induces crossed-long live protection.PloS one · 2020Article
- Identification of Plasmodium falciparum circumsporozoite protein-specific CD8+ T cell epitopes in a malaria exposed population.PloS one · 2020Article
- Controlled Infection Immunization Using Delayed Death Drug Treatment Elicits Protective Immune Responses to Blood-Stage Malaria Parasites.Infection and immunity · 2019Article
- A step forward for an attenuated blood-stage malaria vaccine.BMC medicine · 2018Article
- Immunization with Transgenic Rodent Malaria Parasites Expressing Pfs25 Induces Potent Transmission-Blocking Activity.Scientific reports · 2018Article
- Protein-Specific Features Associated with Variability in Human Antibody Responses toThe American journal of tropical medicine and hygiene · 2018Article
- Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of RecombinantInfection and immunity · 2018Article
- Induction of immunity following vaccination with a chemically attenuated malaria vaccine correlates with persistent antigenic stimulation.Clinical & translational immunology · 2018Article
- A whole parasite transmission-blocking vaccine for malaria: an ignored strategy.Emerging topics in life sciences · 2017Article
- Vaccines to Accelerate Malaria Elimination and Eventual Eradication.Cold Spring Harbor perspectives in medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccine development for the blood stages of malaria has focused on the induction of antibodies to parasite surface antigens, most of which are highly polymorphic. An alternate strategy has evolved from observations that low-density infections can induce antibody-independent immunity to different strains. To test this strategy, we treated parasitized red blood cells from the rodent parasite Plasmodium chabaudi with seco-cyclopropyl pyrrolo indole analogs. These drugs irreversibly alkylate parasite DNA, blocking their ability to replicate. After administration in mice, DNA from the vaccine could be detected in the blood for over 110 days and a single vaccination induced profound immunity to different malaria parasite species. Immunity was mediated by CD4+ T cells and was dependent on the red blood cell membrane remaining intact. The human parasite, Plasmodium falciparum, could also be attenuated by treatment with seco-cyclopropyl pyrrolo indole analogs. These data demonstrate that vaccination with chemically attenuated parasites induces protective immunity and provide a compelling rationale for testing a blood-stage parasite-based vaccine targeting human Plasmodium species.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.